


1/127

FIG. 1



2/127

FIG. 2






FIG. 3




4/127

FIG. 4



5/127

FIG. 5






FIG. 7







FIG. 8





9/127

FIG. 10A-10C



10/127

FIG. 11A




FIG. 11B




FIG. 11C





FIG. 11D



14/127

FIG. 12





FIG. 13



15/127

FIG. 14





FIG. 15A



16/127

FIG. 15B





FIG. 16



17/127

FIG. 17





FIG. 18A



18/127

FIG. 18B





FIG. 19A



19/127

FIG. 19B





FIG. 19C



20/127

FIG. 20




FIG. 21






FIG. 22



Dotted box or parentheses, test not mandatory, prescreening Fibrosis values may be used for liver biopsy eligibility



23/127

FIG. 24A






FIG. 24B




24/127

FIG. 25A



Paired Biopsy Population (both baseline and  
Week 52 not placebo corrected)


FIG. 25B



Paired Biopsy Population (both baseline and  
Week 52 not placebo corrected)


25/127

FIG. 26A



ITT Population (% response after subtracting the placebo % response, missing biopsies are non responders)


FIG. 26B



ITT Population (% response after subtracting the placebo % response, missing biopsies are non responders)

26/127


FIG. 27



All resmetirom treated patients (80 mg and 100 mg combined)  
Logistic regression model, predicting response on biopsy as a function of  
% change from baseline in MRI-PDFF


27/127

FIG. 28




28/127

FIG. 29A



ALT response at least 20% improvement or 17IU; worsening at least 20%


FIG. 29B



ALT response at least 20% improvement or 17IU; worsening at least 20%


29/127

FIG. 30A



— Placebo — Resmetirom 80mg — Resmetirom 100 mg


FIG. 30B



— Placebo — Resmetirom 80mg — Resmetirom 100 mg


30/127

FIG. 31



\*All resmetirom treated patients (80 mg and 100 mg combined). VCTE, vibration- controlled transient elastography.

FIG. 32A




<sup>b</sup>Fibrosis improvement response:  $\geq 1$  stage improvement in fibrosis with no worsening of NAS

<sup>c</sup>Worsening was determined only in F1B/F2 patients by pathologists; worsening on qFibrosis is not directly linked to an ordinal fibrosis score

\* All P values are nominal.

31/127

FIG. 32B




<sup>b</sup> Fibrosis improvement response:  $\geq 1$  stage improvement in fibrosis with no worsening of NAS

<sup>c</sup> Worsening was determined only in F1B/F2 patients by pathologists; worsening of qFibrosis is not directly linked

\* All P values are nominal.

32/127


FIG. 33A



\*80mg/100mg combined

33/127


FIG. 33B



\*80mg/100mg combined


34/127

FIG. 34A




35/127

FIG. 34B




36/127

FIG. 35A



37/127

FIG. 35B



38/127

FIG. 36





FIG. 37



39/127

FIG. 38





FIG. 39



40/127

FIG. 40






FIG. 41



41/127

**FIG. 42**


Response Predictors of Resmetirom NASH Resolution  
Response: 52 Week Data



42/127


**FIG. 43**

Important Predictors of Resmetirom Fibrosis  
Improvement Biopsy Response: 52 Week data



43/127

FIG. 44

Figure 1. P3NP Change vs. PRO-C3 at Week 52<sup>1</sup><sup>1</sup>X-axis truncated to exclude extreme values

44/127

FIG. 45

Figure 2. ELF Change vs. PRO-C3 Change at Week 52


<sup>1</sup>X-axis truncated to exclude extreme values

FIG. 46

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Recommended Dosage and Administration

The recommended dosage of REZDIFFRA is based on actual body weight. For patients weighing:

- <100kg, the recommended dosage is 80 mg orally once daily.
- ≥100kg, the recommended dosage is 100 mg orally once daily.

45/127

FIG. 47





FIG. 48



46/127

FIG. 49





FIG. 50



47/127

FIG. 51





FIG. 52



48/127

FIG. 53





FIG. 54



49/127

FIG. 55

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom L-proline salt Form R3-A.





FIG. 56

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form R3-A Resmetirom: L-proline co-crystal (full range 200-0 ppm)



50/127

FIG. 57

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form R3-A Resmetirom:  
L-proline co-crystal (200-100 ppm)





FIG. 58

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form R3-A Resmetirom:  
L-proline co-crystal (100-0 ppm)



51/127

FIG. 59

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom:  
nicotinamide form RC1-A





FIG. 60

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC1-A Resmetirom:  
nicotinamide co-crystal (full range 200-0 ppm)



52/127

FIG. 61

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC1-A Resmetirom:  
nicotinamide co-crystal (200-100 ppm)





FIG. 62

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC1-A Resmetirom:  
nicotinamide co-crystal (100-0 ppm)



53/127

FIG. 63

**A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom: caffeine form RC2-A**





FIG. 64

A characteristic solid state <sup>13</sup>C NMR spectrum of Form RC2-A of Resmetirom: caffeine co-crystal (full range 200-0 ppm)



54/127

FIG. 65

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC2-A of Resmetirom: caffeine co-crystal (200-100 ppm)





FIG. 66

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC2-A of Resmetirom: caffeine co-crystal (100-0 ppm)



55/127

FIG. 67

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom: caffeine form RC2-B





FIG. 68

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC2-B of Resmetirom: caffeine co-crystal (full range 200-0 ppm)



56/127

FIG. 69

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC2-B of Resmetirom: caffeine co-crystal (200-100 ppm)





FIG. 70

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form RC2-B of Resmetirom: caffeine co-crystal (100-0 ppm)



57/127

FIG. 71

A characteristic X-ray powder diffraction pattern (XRPD) of  
Resmetirom: 2-picolinic acid form RC3-A





FIG. 72

A characteristic X-ray powder diffraction pattern (XRPD) of  
Resmetirom: caffeine form RC4-A



58/127

FIG. 73

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom N-methyl morpholine salt Form R1-A.





FIG. 74

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom piperazine salt Form R2-A.



59/127

FIG. 75

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form R2-A of Resmetirom piperazine salt (full range 200-0 ppm)





FIG. 76

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form R2-A of Resmetirom piperazine salt (200-100 ppm)



60/127

FIG. 77

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form R2-A of Resmetirom piperazine salt (100-0 ppm)




FIG. 78

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom benzathine salt Form R4-A.




FIG. 79





FIG. 80



62/127

FIG. 81





FIG. 82



63/127

FIG. 83





FIG. 84

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 3.



64/127

FIG. 85

A characteristic X-ray powder diffraction pattern  
(XRPD) of Resmetirom Form 9.





FIG. 86



65/127

FIG. 87





FIG. 88

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 2.



66/127

FIG. 89

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 4.





FIG. 90

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 6.



67/127

FIG. 91

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 7.





FIG. 92

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 8.



68/127

FIG. 93

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 10.





FIG. 94

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 11.



69/127

FIG. 95

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 13.





FIG. 96

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 14.



70/127

FIG. 97

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 15.





FIG. 98

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 16.



71/127

FIG. 99

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 17.





FIG. 100

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 19.



72/127

FIG. 101

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 20.





FIG. 102

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 21.



73/127

FIG. 103

A characteristic X-ray powder diffraction pattern (XRPD) of Resmetirom Form 22.





FIG. 104

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form 20 of Resmetirom (full range 200-0 ppm)



74/127

FIG. 105

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form 20 of Resmetirom (200-100 ppm)





FIG. 106

A characteristic solid state  $^{13}\text{C}$  NMR spectrum of Form 20 of Resmetirom (100-0 ppm)



75/127

FIG. 107





FIG. 108



76/127

FIG. 109





FIG. 110



77/127

FIG. 111





FIG. 112



78/127

FIG. 113





FIG. 114



79/127

FIG. 115





FIG. 116



80/127

FIG. 117





FIG. 118



81/127

FIG. 119





FIG. 120



82/127

FIG. 121





FIG. 122



83/127

FIG. 123





FIG. 124



84/127

FIG. 125





FIG. 126



85/127

FIG. 127





FIG. 128



86/127

FIG. 129





FIG. 130



87/127

FIG. 131





FIG. 132



NETZSCH Proteus

88/127

FIG. 133





FIG. 134

Counts



89/127

FIG. 135





FIG. 136



90/127

FIG. 137




FIG. 138





FIG. 139



91/127

FIG. 140





FIG. 141



92/127

FIG. 142





FIG. 143



93/127

FIG. 144





FIG. 145



94/127

FIG. 146




FIG. 147





FIG. 148



95/127

FIG. 149





FIG. 150



96/127

FIG. 151





FIG. 152



97/127

FIG. 153





FIG. 154



98/127

FIG. 155





FIG. 156



99/127

FIG. 157





FIG. 158



100/127

FIG. 159





FIG. 160



101/127

FIG. 161





FIG. 162



102/127

FIG. 163





FIG. 164



103/127

FIG. 165





FIG. 166



SUBSTITUTE SHEET (RULE 26)

104/127

FIG. 167





FIG. 168



105/127

FIG. 169





FIG. 170



106/127

FIG. 171





FIG. 172



107/127

FIG. 173





FIG. 174



108/127

FIG. 175





FIG. 176



109/127

FIG. 177





FIG. 178



110/127

FIG. 179





FIG. 180



111/127

FIG. 181





FIG. 182



112/127

FIG. 183






FIG. 184




113/127

FIG. 185



PlotMon V2.1.1.0

FIG. 186



SUBSTITUTE SHEET (RULE 26)

114/127

FIG. 187





FIG. 188



115/127

FIG. 189





FIG. 190



116/127

FIG. 191





FIG. 192



117/127

FIG. 193






FIG. 194




118/127

FIG. 195



PlotMon V2.1.1.0

FIG. 196



SUBSTITUTE SHEET (RULE 26)

119/127

FIG. 197





FIG. 198



120/127

FIG. 199





FIG. 200



PlotMon V2.1.1.0

121/127

FIG. 201






FIG. 202




122/127

FIG. 203



PlotMon V2.1.1.0


FIG. 204



SUBSTITUTE SHEET (RULE 26)


123/127

FIG. 205



PlotMon V2.1.1.0

FIG. 206



SUBSTITUTE SHEET (RULE 26)

124/127

FIG. 207





FIG. 208



125/127

FIG. 209





FIG. 210



PlotMon V2.1.1.0

126/127

FIG. 211






FIG. 212



127/127

FIG. 213



PlotMon V2.1.1.0